SecBot SecBot
8-K ·Filed May 13, 2026

ANIP

ANI PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001023024-26-000054
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The raised guidance and strong Q1 beat confirm accelerating momentum in Cortrophin Gel and the generics cash flow engine. With a $100M buyback authorization and net leverage at 1.3x, ANI has ample capacity for further capital deployment. Watch for the Phase 4 gout trial data and the full gout sales force deployment by end of Q2 2026 as key catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$80.88
T+0 close · May 13, 2026 · via day close
Latest settled
−3.25%
T+60 · $78.25
Vs SPY
−7.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $80.88entry
  2. T+1 · 6mo ago −1.61%α −2.38% · $79.58
  3. T+5 · 6mo ago −0.69%α +0.47% · $80.32
  4. T+20 · 5mo ago +0.95%α +1.56% · $81.65
  5. T+60 · 3mo ago −3.25%α −7.69% · $78.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising its full-year 2026 guidance originally provided on May 8, 2026. The presentation highlights strong Q1 2026 results with total net revenue of $237.5M (+20% YoY) and adjusted non-GAAP EBITDA of $63.0M (+24% YoY), driven by Cortrophin Gel momentum and a new IP license fee. The company raised its 2026 revenue guidance to $1.08B-$1.14B (from $1.055B-$1.115B) and adjusted EBITDA guidance to $285M-$300M (from $275M-$290M), and authorized a new $100M share repurchase program.

Key Facts

  • Q1 2026 total net revenue of $237.5M, up 20% YoY from $197.1M
  • Q1 2026 adjusted non-GAAP EBITDA of $63.0M, up 24% YoY from $50.7M
  • Raised full-year 2026 total net revenue guidance to $1.08B-$1.14B (prior: $1.055B-$1.115B)
  • Raised full-year 2026 adjusted non-GAAP EBITDA guidance to $285M-$300M (prior: $275M-$290M)
  • Cortrophin Gel net revenue guided to $540M-$575M in 2026, representing ~60% YoY growth
  • Board authorized a new $100M share repurchase program
  • Out-licensed IP to Harmony Biosciences for $15M upfront fee recognized in Q1 2026, plus up to $10M in milestones
  • Cash of $311M as of March 31, 2026; net leverage of ~1.3x

Financial Impact

Raised 2026 revenue guidance by $25M at midpoint ($1.11B vs prior $1.085B) and EBITDA guidance by $10M at midpoint ($292.5M vs prior $282.5M). Q1 revenue grew 20% YoY and EBITDA grew 24% YoY.

revenueebitdaepsshare repurchase

Risk Factors

  • Cortrophin Gel growth dependent on continued market expansion and gout launch execution
  • Blended royalty rate to Merck on Cortrophin Gel expected in high-20% range, pressuring gross margin
  • Generics business faces pricing pressure and FDA competition risks
  • ILUVIEN return to growth not yet confirmed by hard data

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001023024-26-000054
Document: ani-20260513.htm0001023024-26-000054
Document: 0001023024-26-000054-index-headers.html0001023024-26-000054
Document: 0001023024-26-000054-index.html0001023024-26-000054
Document: 0001023024-26-000054.txt0001023024-26-000054

Track record

34 reports on ANIP

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026